CompletedNCT00640185
Safety study of ABT-089 in ADHD
This study is completed in the United States. It is testing ABT-089 for ADHD.
In United StatesADHDDrugA study involving a medication or substance.From 18 Years to 60 Years
Study directory
Back to overviewMental health studies with practical context.
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
CompletedNCT04035200
Safety study of V117957 in Addiction
This study is completed in the United States. It is testing V117957 for Addiction.
In United StatesAddictionDrugFrom 18 Years to 64 Years
CompletedNCT01879722
Safety study of Multiple Rising Doses of TAK- 063 in schizophrenia
This study is completed in the United States. It is testing Multiple Rising Doses of TAK- 063 for schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 55 Years
CompletedNCT05447286
Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
This study is completed in the United States. It focuses on Addiction.
In United StatesAddictionDrugFrom 21 Years to 58 Years
CompletedNCT03327402
Safety study of SHP465 in ADHD
This study is completed in the United States. It is testing SHP465 for ADHD.
In United StatesADHDDrugFrom 4 Years to 5 Years
CompletedNCT01396447
Safety study of safety, Tolerability, and Efficacy of Cariprazine in Participants With Depression in depression in bipolarity
This study is completed in the United States, in Canada, in Bulgaria, .... It is testing safety, Tolerability, and Efficacy of Cariprazine in Participants With Depression for depression in bipolarity.
In United StatesBipolarity, DepressionDrugFrom 18 Years to 65 Years
CompletedNCT01556763
Safety study of EVP-6124 in schizophrenia
This study is completed in the United States. It is testing EVP-6124 for schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 55 Years
SuspendedNCT02724917
Safety study of APN1125 in schizophrenia
This study is suspended in the United States. It is testing APN1125 for schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 45 Years
CompletedNCT06005402
Safety, Tolerability, and Pharmacokinetics of CSX-1004
This study is completed in the United States. It focuses on Addiction.
In United StatesAddictionBiologicalFrom 18 Years to 50 Years
CompletedNCT01348100
Safety study of iloperidone Depot in Schizophrenia
This study is completed in the United States. It is testing iloperidone Depot for Schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 65 Years
CompletedNCT04779177
Safety study of lumateperone in schizophrenia
This study is completed in the United States. It is testing lumateperone for schizophrenia.
In United StatesSchizophreniaDrugFrom 13 Years to 17 Years
CompletedNCT06627413
Safety study of Lumateperone Long-Acting Injectable Formulations in schizophrenia
This study is completed in the United States. It is testing Lumateperone Long-Acting Injectable Formulations for schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 55 Years
Public registry coverage is progressing
HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.